Skip to main content
SpringerLink
Log in

Urticaria and Angioedema

  • Chapter
  • First Online:
Asthma, Allergic and Immunologic Diseases During Pregnancy

  • 608 Accesses

Abstract

Urticaria and angioedema can manifest throughout pregnancy with an impact ranging from a decline in one’s quality of life to a potentially life-threatening situation in some cases of hereditary angioedema. Management should be tailored for each patient based on her history, personal priorities, severity of disease, and potential complications. As medication use is typically avoided in pregnancy if possible, due to actual or perceived risks to the fetus, women are often undertreated. In women with pre-existing chronic urticaria/angioedema, a thorough conversation between the clinician and patient should take place, ideally prior to conception, on the risks and benefits of therapy throughout pregnancy and lactation. Both acute and chronic urticaria present similarly in pregnant and nonpregnant patients. They should both be managed with second-generation H1 antihistamines as first-line therapy as they have reassuring human safety data during pregnancy. First-generation H1 antihistamines are generally considered second-line agents due to their sedating effects. Systemic steroids may have a role in short-term management but should never be used as chronic treatment for urticarial lesions. The use of omalizumab for chronic urticaria during pregnancy appears to be a safe and effective option, but data remain limited, and therefore omalizumab should be used only after a failure of first-line treatment. Special considerations exist for lactating mothers with urticaria. Second-generation H1 antihistamines again are the preferred therapy due to very low levels being detected in breast milk. Hereditary angioedema (HAE) is due to dysfunction of C1 inhibitor and can have an unpredictable course during pregnancy with a slight majority of women reporting an aggravation of symptoms. The safest option for acute exacerbations, short-term prophylaxis, and chronic prophylaxis is C1-INH concentrate. Other therapies for HAE including attenuated androgens, fresh frozen plasma, tranexamic acid, icatibant, and ecallantide have not been shown to be safe to use during pregnancy or have had inferior outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McKee WD. The incidence and familial occurrence of allergy. J Allergy Ther. 1966;38(4):226–35.

    Article  CAS  Google Scholar 

  2. Sheldon JM, Mathews KP, Lovell RG. The vexing urticaria problem: present concepts of etiology and management. J Allergy Ther. 1954;25(6):525–60.

    Article  CAS  Google Scholar 

  3. Simonart T, Askenasi R, Lheureux P. Particularities of urticaria seen in the emergency department. Eur J Emerg Med. 1994;1(2):80–2.

    Article  CAS  PubMed  Google Scholar 

  4. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–7.

    Article  PubMed  Google Scholar 

  5. Frigas E, Nzeako UC. Angioedema. Pathogenesis, differential diagnosis, and treatment. Clin Rev Allergy Immunol. 2002;23(2):217–31.

    Article  PubMed  Google Scholar 

  6. Malbrán E, Fernández Romero D, Juri MC, Larrauri BJ, Malbrán A. Epidemiology of angioedema without wheals in an allergy and immunology center. Med (B Aires). 2015;75(5):273–6.

    Google Scholar 

  7. Gabbe SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ERM, et al. Obstetrics: normal and problem pregnancies. 7th ed. Philadelphia: Elsevier; 2016.

    Google Scholar 

  8. Zaitsu M, Narita S, Lambert KC, Grady JJ, Estes DM, Curran EM, et al. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol. 2007;44(8):1977–85.

    Article  CAS  PubMed  Google Scholar 

  9. Cocchiari R, Albeggiani G, Di Trapani G, Azzolina A, Lampiasi N, Rizzo F, et al. Modulation of rat peritoneal mast cell and human basophil histamine release by estrogens. Int Arch Allergy Appl Immunol. 1990;93(2–3):192–7.

    Article  Google Scholar 

  10. Mittman RJ, Bernstein DI, Steinberg DR, Enrione M, Bernstein IL. Progesterone-responsive urticaria and eosinophilia. J Allergy Clin Immunol. 1989;84(3):304–10.

    Article  CAS  PubMed  Google Scholar 

  11. Vasiadi M, Kempuraj D, Boucher W, Kalogeromitros D, Theoharides TC. Progesterone inhibits mast cell secretion. Int J Immunopathol Pharmacol. 2006;19(4):787–94.

    Article  CAS  PubMed  Google Scholar 

  12. Kasperska-Zajac A, Brzoza Z, Rogala B. Sex hormones and urticaria. J Dermatol Sci. 2008;52(2):79–86.

    Article  CAS  PubMed  Google Scholar 

  13. Incorvaia E, Sicouri L, Petersen-Mahrt SK, Schmitz KM. Hormones and AID: balancing immunity and autoimmunity. Autoimmunity. 2013;46(2):128–37.

    Article  CAS  PubMed  Google Scholar 

  14. Zierau O, Zenclussen AC, Jensen F. Role of female sex hormones. Estradiol and progesterone, in mast cell behavior. Front Immunol. 2012;3:169.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Slater JE, Kaliner M. Effects of sex hormones on basophil histamine release in recurrent idiopathic anaphylaxis. J Allergy Clin Immunol. 1987;80:285–90.

    Article  CAS  PubMed  Google Scholar 

  16. Kasperska-Zajac A, Brzoza Z, Rogala B. Serum concentration of dehydroepiandrosterone sulphate in female patients with chronic idiopathic urticaria. J Dermatol Sci. 2006;41(1):80–1.

    Article  CAS  PubMed  Google Scholar 

  17. Thon V, Harle P, Scholmerich J, Kuklinek P, Lokaj J, Straub RH. Lack of dehydroepiandrosterone in type I and II hereditary angioedema and role of danazol in steroid hormone conversion. Allergy. 2007;62(11):1320–5.

    Article  CAS  PubMed  Google Scholar 

  18. Tagawa N, Hidaka Y, Takano T, Shimaoka Y, Kobayashi Y, Amino N. Serum concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfate and their relation to cytokine production during and after normal pregnancy. Clin Chim Acta. 2004;340(1–2):187–93.

    Article  CAS  PubMed  Google Scholar 

  19. Aoki T, Kojima M, Horiko T. Acute urticaria: history and natural course of 50 cases. J Dermatol. 1994;21(2):73–7.

    Article  CAS  PubMed  Google Scholar 

  20. Sehgal VN, Rege VL. An interrogative study of 158 urticaria patients. Ann Allergy. 1973;31(6):279–83.

    CAS  PubMed  Google Scholar 

  21. Sabroe RA. Acute Urticaria. Immunol Allergy Clin N Am. 2014;34(1):11–21.

    Article  Google Scholar 

  22. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869–73.

    Article  CAS  PubMed  Google Scholar 

  23. Kaplan A. Inflammation in chronic urticaria is not limited to the consequences of mast cell (or basophil) degranulation. Clin Exp Allergy. 2010;40(6):834–5.

    Article  CAS  PubMed  Google Scholar 

  24. Saini SS. Basophil responsiveness in chronic urticaria. Curr Allergy Asthma Rep. 2009;9(4):286–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129(5):1307–13.

    Article  PubMed  Google Scholar 

  26. Gruber BL, Baeza ML, Marcheses MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol. 1988;90(2):213–7.

    Article  CAS  PubMed  Google Scholar 

  27. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599–604.

    Article  CAS  PubMed  Google Scholar 

  28. Doong JC, Chichester K, Oliver ET, Schwartz LB, Saini SS. Chronic idiopathic urticaria: systemic complaints and their relationship with disease and immune measures. J Allergy Clin Immunol Pract. 2017;5(5):1314–8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Amsler E, Augey F, Soria A, Baccon-Gibod I, Doutre MS, Mathelier-Fusade P, et al. Chronic urticaria and hormones: is there a link? J Eur Acad Dermatol Venereol. 2016;30(9):1527–30.

    Article  CAS  PubMed  Google Scholar 

  30. Snyder JL, Krishnaswamy G. Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review. Ann Allergy Asthma Immunol. 2003;90(5):469–77.

    Article  PubMed  Google Scholar 

  31. Li RC, Buchheit KM, Bernstein JA. Progestogen hypersensitivity. Curr Allergy Asthma Rep. 2018;18(1):1.

    Article  PubMed  CAS  Google Scholar 

  32. Bierman SM. Autoimmune progesterone dermatitis of pregnancy. Arch Dermatol. 1973;107(6):896–901.

    Article  CAS  PubMed  Google Scholar 

  33. Meggs WJ, Pescovitz OH, Metcalfe D, Loriaux DL, Cutler G, Kaliner M. Progesterone sensitivity as a cause of recurrent anaphylaxis. N Engl J Med. 1984;311(19):1236–8.

    Article  CAS  PubMed  Google Scholar 

  34. Foer D, Buchheit KM, Gargiulo AR, Lynch DM, Castells M, Wickner PG. Progestogen hypersensitivity in 24 cases: diagnosis, management, and proposed renaming and classification. J Allergy Clin Immunol Pract. 2016;4(4):723–9.

    Article  PubMed  Google Scholar 

  35. Taylor D, Pappo E, Aronson IK. Polymorphic eruption of pregnancy. Clin Dermatol. 2016;34(3):383–91.

    Article  PubMed  Google Scholar 

  36. Holmes RC, Black MM. The specific dermatoses of pregnancy. J Am Acad Dermatol. 1983;8(3):405–12.

    Article  CAS  PubMed  Google Scholar 

  37. Im S, Lee ES, Kim W, Song J, Kim J, Lee M, et al. Expression of progesterone receptor in human keratinocytes. J Korean Med Sci. 2000;15(6):647–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ohel I, Levy A, Silberstein T, Holcberg G, Sheiner E. Pregnancy outcome of patients with pruritic urticarial papules and plaques of pregnancy. J Matern Fetal Neonatal Med. 2006;19(5):305–8.

    Article  PubMed  Google Scholar 

  39. Regnier S, Fermand V, Levy P, Uzan S, Aractingi S. A case-control study of polymorphic eruption of pregnancy. J Am Acad Dermatol. 2008;58(1):63–7.

    Article  PubMed  Google Scholar 

  40. Yancey KB. Herpes gestationis. Dermatol Clin. 1990;8(4):727–35.

    Article  CAS  PubMed  Google Scholar 

  41. Lehrhoff S, Pomeranz MK. Specific dermatoses of pregnancy and their treatment. Dermatol Ther. 2013;26(4):274–84.

    Article  PubMed  Google Scholar 

  42. Chi CC, Wang SH, Charles-Holmes R, Ambros-Rudolph C, Powell J, Jenkins R, et al. Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes. Br J Dermatol. 2009;160(6):1222–8.

    Article  PubMed  Google Scholar 

  43. Amato L, Mei S, Gallerani I, Moretti S, Fabbri P. J Am Acad Dermatol. 2003;49(2):302–7.

    Article  PubMed  Google Scholar 

  44. Diav-Citrin O, Schechtman S, Aharonovich A, Moerman L, Arnon J, Wajnberg R, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol. 2003;111(6):1239–43.

    Article  CAS  PubMed  Google Scholar 

  45. Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. Drug Saf. 2017;40(2):121–32.

    Article  CAS  PubMed  Google Scholar 

  46. Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA. Expert Opin Drug Saf. 2014;13(12):167–98.

    Article  CAS  Google Scholar 

  47. Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol. 2003;111(3):479–83.

    Article  CAS  PubMed  Google Scholar 

  48. Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev. 2012;3:CD008596.

    Google Scholar 

  49. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of Urticaria. The 2017 revision and update. Allergy. 2018. https://doi.org/10.1111/all.

  50. Jain V, Gordon C. Managing pregnancy in inflammatory rheumatological diseases. Arthiritis Res Ther. 2011;13(1):206.

    Article  Google Scholar 

  51. Bay Bjorn AM, Ehrenstein V, Hundborg HH, Nohr EA, Sorensen HT, Norgaard M. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21(2):73–80.

    Article  PubMed  Google Scholar 

  52. Sarkar M, Koren G, Kalra S, Ying A, Smorlesi C, De Santis M, et al. Montelukast use during pregnancy: a multicenter, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol. 2009;65(12):1259–64.

    Article  CAS  PubMed  Google Scholar 

  53. Joshi S, Khan DA. The expanding field of biologics in the management of chronic urticaria. J Allergy Clin Immunol Pract. 2017;5(6):1489–99.

    Article  PubMed  Google Scholar 

  54. Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–12.

    Article  CAS  PubMed  Google Scholar 

  55. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicyclic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25(2):271–5.

    Article  CAS  PubMed  Google Scholar 

  56. O’Brien TE. Excretion of drugs in human milk. Am J Hosp Pharm. 1974;31(9):844–54.

    PubMed  Google Scholar 

  57. Hilbert J, Radwanski E, Affrime MB, Perentesis G, Symchowicz S, Zampaglione N. Excretion of loratadine in human breast milk. J Clin Pharmacol. 1988;28(3):234–9.

    Article  CAS  PubMed  Google Scholar 

  58. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393–9.

    Article  CAS  PubMed  Google Scholar 

  59. Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Investig. 1985;8(2):143–6.

    Article  CAS  Google Scholar 

  60. Lumry WR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care. 2013;19(7 Suppl):s103–10.

    PubMed  Google Scholar 

  61. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129(2):308–20.

    Article  PubMed  Google Scholar 

  62. Cunningham DS, Jensen JT. Hereditary angioneurotic edema in the puerperium. A case report. J Reprod Med. 1991;36(4):312–3.

    CAS  PubMed  Google Scholar 

  63. Cohen AJ, Laskin C, Tarlo S. C1 esterase inhibitor in pregnancy. J Allergy Clin Immunol. 1992;90(3 Pt 1):412–3.

    Article  CAS  PubMed  Google Scholar 

  64. Weiler CR, van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin Proc. 2006;81(7):958–72.

    Article  CAS  PubMed  Google Scholar 

  65. Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484.e1–4.

    Article  Google Scholar 

  66. Czaller I, Visy B, Czuka D, Fust G, Toth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):44–9.

    Article  CAS  PubMed  Google Scholar 

  67. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Heller C, Klingebiel T, Kruez W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitory concentrate. Am J Obstet Gynecol. 2010;203(2):131.e1–7.

    Article  CAS  Google Scholar 

  68. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71(4):206–15.

    Article  CAS  Google Scholar 

  69. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–16.

    Article  CAS  PubMed  Google Scholar 

  70. Caballero T, Canabal J, Rivero-Paparoni D, Cabanas R. Management of hereditary angioedema in pregnant women: a review. Int J Womens Health. 2014;6:839–48.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Kaminsky LW, Kelbel T, Ansary F, Craig T. Multiple doses of icatibant used during pregnancy. Allergy Rhinol (Providence). 2017;8(3):178–81.

    Article  Google Scholar 

  72. Farkas H, Kohalmi KV, Veszeli N, Toth F, Varga L. First report of icatibant treatment in a pregnant patient with hereditary angioedema. J Obstet Gynaecol Res. 2016;42(8):1026–8.

    Article  PubMed  Google Scholar 

  73. Chan W, Berlin N, Sussman GL. Management of hereditary angioedema with C1-inhibitor concentrate during two successive pregnancies. Int J Gynaecol Obstet. 2013;120(2):189–90.

    Article  PubMed  Google Scholar 

  74. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol. 1991;87(4):768–73.

    Article  CAS  PubMed  Google Scholar 

  75. Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J Allergy Clin Immunol. 2017;140(1):242–8.e2.

    Article  CAS  PubMed  Google Scholar 

  76. Sinert R, Levy P, Bernstein JA, Body R, Sivilotti MLA, Moellman J, et al. Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema. J Allergy Clin Immunol Pract. 2017;5(5):1402–9.e3.

    Article  PubMed  Google Scholar 

  77. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120(4):979–81.

    Article  CAS  PubMed  Google Scholar 

  78. Staubach P, Metz M, Chapman-Rothe N, Sider C, Brautigam M, Canvin K, et al. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135–44.

    Article  CAS  PubMed  Google Scholar 

  79. Staubach P, Metz M, Chapman-Rothe N, Sieder C, Brautigam M, Maurer M, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2017. https://doi.org/10.1111/all.

Download references

Author information

Authors and Affiliations

  1. Oregon Health and Science University, Portland, OR, USA

    Shyam R. Joshi

  2. University of Texas Southwestern Medical Center, Dallas, TX, USA

    David A. Khan

Authors
  1. Shyam R. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Khan .

Editor information

Editors and Affiliations

  1. Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, CA, USA

    Jennifer A. Namazy

  2. Department of Allergy, Kaiser Permanente Medical Center, San Diego, CA, USA

    Michael Schatz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Joshi, S.R., Khan, D.A. (2019). Urticaria and Angioedema. In: Namazy, J., Schatz, M. (eds) Asthma, Allergic and Immunologic Diseases During Pregnancy. Springer, Cham. https://doi.org/10.1007/978-3-030-03395-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03395-8_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03394-1

  • Online ISBN: 978-3-030-03395-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation